METHOD FOR ASSESSING CLINICAL EFFECTIVENESS OF PROKINETICS OF VARIOUS GROUPS OF PATIENTS SUFFERING FROM AGGRAVATED CHRONIC OBSTRUCTIVE PULMONARY DISEASE Russian patent published in 2014 - IPC A61B5/04 A61K31/166 A61P1/06 

FIELD: medicine.

SUBSTANCE: invention refers to therapy and gastroenterology, and can be used to assess the effectiveness of prokinetics at a various degree of bradientery in patients with aggravated chronic obstructive pulmonary disease (COPD) receiving standard therapy, and a prokinetic or a combination of prokinetics. That is ensured by calculating an average bradientery index (index) before the beginning of the therapy and on the 11th day from the beginning of the therapy with scoring a circadian rhythm regularity of the intestinal evacuation function. If the patient has a stool 7 days a week, zero points are assigned; if he/she has a stool 5-6 days - one point is assigned; 3-4 days - two points, 1-2 days - three points. The formula index=(P₀+P₁+P₂+P₃) /P_com, wherein P₀ is the number of patients in the group having zero points, P₁ - having one point, P₂ - having two points, P₃ - having three points; P_com is the number of patients in the group. That is followed by calculating a bradientery manifestation coefficient Cbm by formula Cbm=(index 11 day /index 1 day)×100%, wherein index 1 day is the bradientery index before the beginning of the treatment; index 11 day is the bradientery index on the 11^th day of the treatment. If Cbm makes more than 70%, then the clinical effect of the prokinetic is considered to be unpronounced. If Cbm makes 40% to 70%, the moderate manifestation of the clinical effect of the prokinetic is considered. If Cbm is less than 40%, the clinical effect of the prokinetic is considered to be adequate for the correction of the motor evacuation dysfunction of the gastrointestinal tract.

EFFECT: providing the clinical assessment of the clinical effectiveness of the prokinetics of various groups, as well as enabling the selection of the most optimal preparation for the correction of the gastrointestinal motility disorders in the patients with COPD.

2 tbl